Multiple Sclerosis & Cannabis
Track spasticity, fatigue, and pain symptoms against product chemistry. Build personal predictions based on your data.
Multiple sclerosis (MS) is a chronic autoimmune condition affecting the central nervous system. Some MS patients report exploring cannabis alongside their prescribed treatments to manage symptoms like spasticity, pain, and fatigue.
TOQidex helps you track 10 MS-specific symptoms against each product's measured chemistry, building a personal dataset over time. This data can support more informed conversations with your neurologist or care team.
10 Symptoms, Tied to Chemistry
Cannabis & Multiple Sclerosis
Cannabis and MS is an area of active research, with some jurisdictions having approved cannabis-based medications specifically for MS spasticity. Here is what some of the current literature explores:
- Spasticity research: Nabiximols (a cannabis-derived pharmaceutical) has been approved in some countries for MS-related spasticity. This is a specific pharmaceutical product, not the same as whole-plant cannabis.
- Pain reports: Some MS patients report that certain cannabis products correlate with changes in their pain experience. This is self-reported data, not clinical evidence for whole-plant cannabis.
- Fatigue considerations: The relationship between cannabis and MS-related fatigue is complex. Some users report benefits while others report increased fatigue with certain products.
Important: MS is a serious neurological condition requiring professional medical care. TOQidex does not make medical claims. The platform tracks your self-reported responses only. Always work with your neurologist regarding treatment decisions.
Component of nabiximols, which has been studied for MS spasticity.
Component of nabiximols. Being studied for neuroprotective potential.
Early research into anti-inflammatory and neuroprotective properties.
Some users associate with muscle relaxation. Not clinically validated for MS.
Calming properties being studied. Preliminary evidence only.
Anti-inflammatory CB2 research ongoing.
Frequently Asked Questions
Is cannabis approved for MS?
Nabiximols (Sativex), a cannabis-derived pharmaceutical, is approved for MS spasticity in some countries. TOQidex tracks your responses to whole-plant products, which are different from pharmaceuticals.
Can I use TOQidex data with my neurologist?
Yes. Your tracking data can support more informed conversations with your care team about your experience with different products.
From the Blog
Why Strain Names Are Unreliable (And What to Track Instead)
A study of 89,923 cannabis samples found that indica, sativa, and hybrid labels showed "no obvious segregation" against actual chemistry. Only 4 of 30 strains maintained consistent profiles across dispensaries. Here is what the research says.
Cannabinoids and Terpenes: The Chemistry That Drives Your Cannabis Experience
THC percentage is one data point. Your cannabis experience is shaped by at least 8 major cannabinoids and 9 dominant terpenes working together. Here is what the current research says about each compound.
Why TOQidex Tracks These 13 Medical Conditions
Over 6 million Americans hold medical cannabis cards. The conditions they manage are not random. Here is the data behind the 13 conditions TOQidex supports, why we chose them, and what the research says about patient-reported outcomes.
Other Conditions We Track
Start Tracking Your Experience
Join TOQidex to track how different products affect your symptoms.
Sign Up FreeTOQidex tracks user-reported symptom response. It does not diagnose, treat, cure, or prevent any condition. All outputs reflect probability based on your personal logged data.